The S&P 500 Index ($SPX ) (SPY ) closed up by +0.33% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%.  December E-mini S&P futures (ESZ26 ) rose +0.28%, and December E-mini...

Stocks Settle Mixed as Broader Market Recovers from Chip Stock Rout

The S&P 500 Index ($SPX ) (SPY ) is up by +0.13% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.57%.  December E-mini S&P futures (ESZ26 ) are up +0158%, and December E-mini...

Stock Indexes Rebound as Investors Rotate Out of Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) is down by -0.57% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.71%.  December E-mini S&P futures (ESZ26 ) are down -0.58%, and December E-mini...

Stocks Pressured as Chipmaker Selloff Deepens

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Amplify CWP Enhanced Dividend Income ETF (Symbol: DIVO) where we have detected an approximate $99.9 million dollar outflow -- that's a 1.2% decrease

Noteworthy ETF Outflows: DIVO, V, AMGN, XLY

Key PointsBoeing's board now has more directors with deep aviation experience.

Boeing's Secret Weapon Isn't on the Factory Floor -- It's in the Boardroom

The S&P 500 Index ($SPX ) (SPY ) closed down by -1.11% on Wednesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.02%.  December E-mini S&P futures (ESZ26 ) fell -1.16%, and December E-mini...

Stocks Sharply Lower on Inflation Woes and Slumping Chipmakers

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc. News